Retinagenix Holdings Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

Retinagenix Holdings General Information

Description

Operator of a clinical-stage biopharmaceutical company intended to address medical needs in genetically determined orphan diseases of the eye. The company's lead product candidate, Zuretinol Acetate is an oral therapy used for the treatment of rare forms of childhood blindness in patients.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 1815 Purdy Avenue
  • Miami beach, FL 33139
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Corporate Office
  • 1815 Purdy Avenue
  • Miami beach, FL 33139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Retinagenix Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Retinagenix Holdings‘s full profile, request access.

Request a free trial

Retinagenix Holdings Patents

Retinagenix Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230321024-A1 Methods of treating visual disorders using daily low dosing of a retinoid compound Pending 09-Jun-2020
WO-2021252421-A1 Methods of treating visual disorders using daily low dosing of a retinoid compound Inactive 09-Jun-2020
EP-2819667-B1 Retinal derivatives for use in improving visual function Active 01-Mar-2012
EP-2819667-B8 Retinal derivatives for use in improving visual function Active 01-Mar-2012
ES-2780357-T3 Retinal derivatives for use in improving visual function Active 01-Mar-2012 A61K31/11
To view Retinagenix Holdings’s complete patent history, request access »

Retinagenix Holdings Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Retinagenix Holdings‘s full profile, request access.

Request a free trial

Retinagenix Holdings FAQs

  • When was Retinagenix Holdings founded?

    Retinagenix Holdings was founded in 2004.

  • Where is Retinagenix Holdings headquartered?

    Retinagenix Holdings is headquartered in Miami beach, FL.

  • What industry is Retinagenix Holdings in?

    Retinagenix Holdings’s primary industry is Drug Discovery.

  • Is Retinagenix Holdings a private or public company?

    Retinagenix Holdings is a Private company.

  • What is Retinagenix Holdings’s current revenue?

    The current revenue for Retinagenix Holdings is .

  • Who are Retinagenix Holdings’s investors?

    BridgeBio Pharma and Novelion Therapeutics have invested in Retinagenix Holdings.

  • When was Retinagenix Holdings acquired?

    Retinagenix Holdings was acquired on 19-Jan-2022.

  • Who acquired Retinagenix Holdings?

    Retinagenix Holdings was acquired by Eluminex Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process